Dasa: Margin Optimization and the Deleveraging Challenge in the Healthcare Sector

Dasa’s net loss reduction to R$ 35 million in Q2 2026 marks an operational turning point, driven by an Ebitda of R$ 446 million—a robust 53% year-over-year expansion. With margins rising 5.8 percentage points to 20.1%, the company demonstrates efficiency despite inflationary pressure on medical supplies. In a high-interest environment with the Selic rate at 14% p.a., Dasa’s ability to generate operational cash flow serves as a critical indicator of resilience. While macroeconomic headwinds like the R$ 5.19 exchange rate and 4.44% IPCA inflation challenge the sector, Dasa’s focus on internal efficiency and deleveraging proves more effective than acquisition-led growth. Investors should monitor the company's ability to maintain Ebitda margins above 20% and reduce gross debt over the next 90 to 180 days to potentially achieve consistent net profitability.